IBRORS-MCL study : a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
© 2022. The Author(s)..
This retrospective study evaluated 66 patients diagnosed with relapsed and/or refractory mantle cell lymphoma (R/R MCL) treated with ibrutinib in Spain in routine clinical practice. At diagnosis, patients had a median age of 64.5 years, 63.6% presented with intermediate/high sMIPI (simplified prognostic index for advanced-stage mantle cell lymphoma), 24.5% had the blastoid variant, and 55.6% had a Ki67 > 30%. Patients had received a median of 2 prior lines of therapy (range 1-2; min-max 1-7). Overall response rate was 63.5%, with 38.1% of patients achieving complete response (CR). With a median duration of ibrutinib exposure of 10.7 months (range 5.2-19.6; min-max 0.3-36), the median progression-free survival (PFS) and overall survival (OS) were 20 months [95% confidence interval (CI) 8.8-31.1] and 32 months (95% CI 22.6-41.3), respectively, and were not reached in patients achieving CR. No grade ≥ 3 cardiovascular toxicity or bleeding was reported. This study supports that treatment with ibrutinib leads to high response rates and favorable survival outcomes in patients with R/R MCL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:116 |
|---|---|
| Enthalten in: |
International journal of hematology - 116(2022), 3 vom: 12. Sept., Seite 381-392 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sancho, Juan-Manuel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1X70OSD4VX |
|---|
| Anmerkungen: |
Date Completed 23.08.2022 Date Revised 23.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12185-022-03367-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340797738 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340797738 | ||
| 003 | DE-627 | ||
| 005 | 20231226010301.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12185-022-03367-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM340797738 | ||
| 035 | |a (NLM)35551632 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sancho, Juan-Manuel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IBRORS-MCL study |b a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.08.2022 | ||
| 500 | |a Date Revised 23.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a This retrospective study evaluated 66 patients diagnosed with relapsed and/or refractory mantle cell lymphoma (R/R MCL) treated with ibrutinib in Spain in routine clinical practice. At diagnosis, patients had a median age of 64.5 years, 63.6% presented with intermediate/high sMIPI (simplified prognostic index for advanced-stage mantle cell lymphoma), 24.5% had the blastoid variant, and 55.6% had a Ki67 > 30%. Patients had received a median of 2 prior lines of therapy (range 1-2; min-max 1-7). Overall response rate was 63.5%, with 38.1% of patients achieving complete response (CR). With a median duration of ibrutinib exposure of 10.7 months (range 5.2-19.6; min-max 0.3-36), the median progression-free survival (PFS) and overall survival (OS) were 20 months [95% confidence interval (CI) 8.8-31.1] and 32 months (95% CI 22.6-41.3), respectively, and were not reached in patients achieving CR. No grade ≥ 3 cardiovascular toxicity or bleeding was reported. This study supports that treatment with ibrutinib leads to high response rates and favorable survival outcomes in patients with R/R MCL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Clinical practice | |
| 650 | 4 | |a Ibrutinib | |
| 650 | 4 | |a Mantle-cell lymphoma | |
| 650 | 4 | |a Real-world evidence | |
| 650 | 4 | |a Relapsed/refractory | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a ibrutinib |2 NLM | |
| 650 | 7 | |a 1X70OSD4VX |2 NLM | |
| 650 | 7 | |a Adenine |2 NLM | |
| 650 | 7 | |a JAC85A2161 |2 NLM | |
| 700 | 1 | |a Marín-Niebla, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Capote, Francisco-Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Cañigral, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Grande, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Donato, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Zeberio, Izaskun |e verfasserin |4 aut | |
| 700 | 1 | |a Puerta, Jose-Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Rivas, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Ceballos, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Vale, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Martín García-Sancho, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Salar, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a González-Barca, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Teruel, Anabel |e verfasserin |4 aut | |
| 700 | 1 | |a Pastoriza, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Conde-Royo, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-García, Joaquín |e verfasserin |4 aut | |
| 700 | 1 | |a Barrenetxea, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Arranz, Reyes |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Rivas, José-Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez, María-José |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez, Aroa |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio-Azpeitia, Eva |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of hematology |d 1997 |g 116(2022), 3 vom: 12. Sept., Seite 381-392 |w (DE-627)NLM012627607 |x 1865-3774 |7 nnns |
| 773 | 1 | 8 | |g volume:116 |g year:2022 |g number:3 |g day:12 |g month:09 |g pages:381-392 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12185-022-03367-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 116 |j 2022 |e 3 |b 12 |c 09 |h 381-392 | ||